Gd(iii)-Pt(iv) theranostic contrast agents for tandem MR imaging and chemotherapy

38Citations
Citations of this article
34Readers
Mendeley users who have this article in their library.

Abstract

Pt(iv) prodrugs have emerged as versatile therapeutics for addressing issues regarding off-target toxicity and the chemoresistance of classic Pt(ii) drugs such as cisplatin and carboplatin. There is significant potential for Pt(iv) complexes to be used as theranostic agents, yet there are currently no reported examples of Gd(iii)-Pt(iv) agents for simultaneous MR imaging and chemotherapy. Here we report the synthesis, characterization, and in vitro efficacy of two Gd(iii)-Pt(iv) agents, GP1 and GP2. Both agents are water soluble and stable under extracellularly relevant conditions but are reduced under intracellular conditions. Both are cytotoxic in multiple cancer cell lines, cell permeable, and significantly enhance the T1-weighted MR contrast of multiple cell lines. Thus, GP1 and GP2 are promising agents for tandem MR imaging and chemotherapy and provide a versatile platform through which future Gd(iii)-Pt(iv) agents can be developed.

Cite

CITATION STYLE

APA

Adams, C. J., & Meade, T. J. (2020). Gd(iii)-Pt(iv) theranostic contrast agents for tandem MR imaging and chemotherapy. Chemical Science, 11(9), 2524–2530. https://doi.org/10.1039/c9sc05937g

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free